Cochrane Review Group
Haematology
78 systematic reviews in Haematology ask 987 questions. 25.9% have no studies to answer them, 21% rest on very low certainty evidence and 21.6% reach moderate or high certainty.
Reviews
78
Questions
987
current versions
No studies
25.9%
Moderate or high
21.6%
No studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 1 [0.27, 3.7] | 3 studies · 451 participants | Very low |
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 3 studies · 431 participants | Very low |
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.71 [0.47, 1.05] | 2 studies · 400 participants | Very low |
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 78
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia
CochraneSoF table
2 questions
Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL)
CochraneSoF table
5 questions
Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors
CochraneSoF table
4 questions